Fundviser Capital (India) Limited (BOM:530197)
India · Delayed Price · Currency is INR 165.10
+0.05 (0.03%)
At close: Aug 11, 2025
Orchard Therapeutics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 502.42 | 332.84 | 9.65 | 2.11 | 1.51 | 2.41 | Upgrade |
Other Revenue | 8.24 | 4.14 | 0.09 | 0.1 | 0.21 | 5.93 | Upgrade |
| 510.65 | 336.98 | 9.74 | 2.22 | 1.72 | 8.34 | Upgrade | |
Revenue Growth (YoY) | 5015.75% | 3360.81% | 339.51% | 29.18% | -79.43% | 187.77% | Upgrade |
Cost of Revenue | 401.23 | 242.16 | - | - | - | - | Upgrade |
Gross Profit | 109.43 | 94.82 | 9.74 | 2.22 | 1.72 | 8.34 | Upgrade |
Selling, General & Admin | 4.98 | 3.72 | 1.13 | 1.26 | 1.46 | 1.44 | Upgrade |
Other Operating Expenses | 61.68 | 61 | 2.68 | 1.03 | -0 | 0.16 | Upgrade |
Operating Expenses | 67.08 | 64.97 | 3.81 | 2.3 | 1.46 | 1.6 | Upgrade |
Operating Income | 42.34 | 29.85 | 5.92 | -0.08 | 0.25 | 6.73 | Upgrade |
Interest Expense | -1.62 | -1.21 | - | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | -0.24 | -0.24 | - | - | -0.35 | -0.35 | Upgrade |
EBT Excluding Unusual Items | 40.48 | 28.4 | 5.92 | -0.08 | -0.1 | 6.38 | Upgrade |
Pretax Income | 40.48 | 28.4 | 5.92 | -0.08 | -0.1 | 6.38 | Upgrade |
Income Tax Expense | 2.3 | 1.75 | 1.49 | 0.02 | 0.23 | 1.14 | Upgrade |
Earnings From Continuing Operations | 38.18 | 26.65 | 4.43 | -0.1 | -0.33 | 5.24 | Upgrade |
Net Income to Company | 38.18 | 26.65 | 4.43 | -0.1 | -0.33 | 5.24 | Upgrade |
Minority Interest in Earnings | -17.01 | -10.82 | - | - | - | - | Upgrade |
Net Income | 21.17 | 15.83 | 4.43 | -0.1 | -0.33 | 5.24 | Upgrade |
Net Income to Common | 21.17 | 15.83 | 4.43 | -0.1 | -0.33 | 5.24 | Upgrade |
Net Income Growth | 365.47% | 257.04% | - | - | - | 2460.19% | Upgrade |
Shares Outstanding (Basic) | 3 | 3 | 4 | 4 | 4 | 4 | Upgrade |
Shares Outstanding (Diluted) | 4 | 4 | 4 | 4 | 4 | 4 | Upgrade |
Shares Change (YoY) | -0.46% | -21.21% | 12.75% | 7.32% | - | - | Upgrade |
EPS (Basic) | 6.68 | 5.17 | 0.99 | -0.03 | -0.09 | 1.42 | Upgrade |
EPS (Diluted) | 5.84 | 4.50 | 0.99 | -0.03 | -0.09 | 1.42 | Upgrade |
EPS Growth | 367.63% | 353.18% | - | - | - | 2460.20% | Upgrade |
Free Cash Flow | - | -104.38 | -27.8 | -2.1 | 16.46 | -22.35 | Upgrade |
Free Cash Flow Per Share | - | -29.67 | -6.23 | -0.53 | 4.46 | -6.06 | Upgrade |
Gross Margin | 21.43% | 28.14% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade |
Operating Margin | 8.29% | 8.86% | 60.84% | -3.60% | 14.76% | 80.79% | Upgrade |
Profit Margin | 4.15% | 4.70% | 45.53% | -4.55% | -19.22% | 62.85% | Upgrade |
Free Cash Flow Margin | - | -30.98% | -285.52% | -94.61% | 959.88% | -268.17% | Upgrade |
EBITDA | - | 30.1 | - | - | - | - | Upgrade |
EBITDA Margin | - | 8.93% | - | - | - | - | Upgrade |
D&A For EBITDA | - | 0.26 | - | - | - | - | Upgrade |
EBIT | 42.34 | 29.85 | 5.92 | -0.08 | 0.25 | 6.73 | Upgrade |
EBIT Margin | 8.29% | 8.86% | 60.84% | -3.60% | 14.76% | 80.79% | Upgrade |
Effective Tax Rate | 5.68% | 6.17% | 25.15% | - | - | 17.89% | Upgrade |
Revenue as Reported | 510.65 | 336.98 | 9.74 | 2.22 | 1.98 | 8.38 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.